

How to Purchase Our Reports Online

~弊社ウェブページからのオンライン決済によるレポート購入方法~

MP Advisors (IBM Mehta Partners)
B/203, Alkapuri Arcade, R. C., Alkapuri, Vadodara-
390 007, INDIA
Phone: +1.646.657.1016 [USA]
+91.265.232.0059/232.7096 [India]
E-mail: mp@mpadvisor.com
Web: www.mpadvisor.com

- このスライドはMP Advisorsの調査報告書を企業ウェブページからPaypalアカウント、もしくはクレジットカードを用いてオンライン購入する方法を記載しています。
- 銀行間の電子送金を用いての購入をご希望されるお客様は表紙、もしくは末ページお問い合わせに記載されている連絡先までお手数ですがお問い合わせください。



MP Advisors 25 years of experience

Home Our Coverage Meet the Team Our Services **Report Summaries** Buy Reports PARA

MP Advisors - Independent Research Provider - Fundamental BioPharmaceuticals

MP Advisors is an independent investment research firm founded in 1996 with an exclusive speciality in the Pharmaceuticals / Biotechnology sector. Formerly, it was the international affiliate of Mehta Partners LLC. MP Advisors has a highly qualified team of analysts, researchers and financial professionals who exercise the use of proprietary data bases, tools, relevant company and regulatory websites to assemble, assimilate, analyze and interpret the latest and most trustworthy information essential, to explore investment opportunities through fundamental assessment. MP Advisors has insightful information on more than 200 pharma and Biotech companies across the globe as well as publishes timely reports on Para IV litigations, Key opinion leaders (Physician's view) assessment, therapy class review of several classes (e.g. Oral anticoagulants, Hepatitis C, Obesity etc.) and Japan generic opportunities.

How We Add Value

We cast a wide net to unearth the best investment opportunities. Our coverage spans the globe and includes all market caps, offering built-in diversification for investors seeking to compose a sector portfolio with low volatility. We cover over 70+ companies and monitor ~150 promising names. Our conclusions include in-depth analysis of long-term (>1year) investment opportunities along with constant reappraisal of selected short-term (3-6 months) ideas.

BioPharma Outlook

We've helped investors navigate the dynamic BioPharma industry for decades. Our flagship publication, BioPharmaceutical Outlook™ maps the highs and lows of the year, assessing the critical success factors that can shape the industry's future.

Based on extensive research and comprehensive data analysis, this volume is a ready reference for monitoring new developments and their investment and strategic implications. From the macro analysis of over 200 companies arise ~40+ actionable capsules categorized into Global

Japanese Trans
Vietnamese Tra
R

27 Nov 2012	C
	fc
	R
21 Nov 2012	B
	A
	V
21 Nov 2012	N
	G
20 Nov 2012	H
	'I
	V
	fc
	G
20 Nov 2012	A
	R
19 Nov 2012	S
	B
15 Nov 2012	A
	F
	E
	h
12 Nov 2012	C
	D
12 Nov	R

- TOPページ上の検索ボックス、Report Summaries、もしくはBuy Reportsからご希望の内容のレポートを探します。

Report Summaries

To lead in global pharmaceutical and biotechnology strategy and investments by maintaining an in-depth understanding and worldwide perspective on the industry, and to work closely with investors and senior managers to enhance their strategic choices.



↓ Global Bio-Pharma Report - Table of Contents

Report Title :	Roche - GSK - EMILIA: TDM1 ready to take over Tykerb
Published Date :	Mar 30, 2012
Document Type :	Essential (ME12033002)
Geographic Zone :	Europe
Countries :	EUROPE
Abstract :	Today, Roche and Immunogen announced the topline data from EMILIA study which met the primary end point of Progression free survival significantly. The study explored the use of Trastuzumab Emtricitabine (TDM1) against Tykerb and Xeloda in more than 950 patients with HER2 positive metastatic breast cancer whose disease progressed after initial treatment with Herceptin and a taxane based chemotherapy (second line setting). We forecast peak sales of \$500m for TDM1 in this indication and this should come at the expense of GSK's Tykerb, which is the current standard of care in this setting. This is the second study in Herceptin failure patients to demonstrate benefit. Earlier, TDM1 in two Phase III studies, VOGEL and HROP had demonstrated an impressive median PFS of 7.3m and 4.9m as a third line treatment option in patients who have failed Tykerb and/or Herceptin and/or chemotherapies.
For Subscribers :	Download the full document - PDF File (3, 50 KB)
Price \$:	90
Buy Now :	Purchase Report
Authors :	✉ Vital Maschanda ✉ Dr. Vijayakumar R. ✉ Rishi Mehta
Tags & Keywords :	Roche, GSK, Tykerb, Xeloda, TDM1, HER-2 positive, Breast cancer, second line

RECENT PUBLICATIONS

- 27 Nov 2012 Cipla - Market Perform, Cipla's bid for Cipla Medpro - Valuation Reasonable, No Strategic Benefits
- 21 Nov 2012 Bristol-Myers Squibb - Eliquis Approved for SPAF in Europe - Waiting for decision with FDA
- 21 Nov 2012 NATCO PHARMA - Oritiperm, Great Result - More to Come
- 20 Nov 2012 Hepatitis C: UPDATE PostASLD '12 - Progress in IFN-Free Drugs & Vaccines - Gilead and Abbott may be the Top Two Slots - Third Place Goes to ...?
- 20 Nov 2012 AUROBINDO - Udeipenem, Great Result, But Still Not Orot/Woods
- 19 Nov 2012 SUN PHARMA - Oritiperm, Balance Sheet Leaking AT Pay
- 15 Nov 2012 ASTRAZENCA - First in class Fingla (dapagliflozin) approved in Europe - Diabetes portfolio may lead AstraZenca's pain
- 12 Nov 2012 Celgene - ABRAXANE - Pipeline Drugs - Long Term Growth!
- 12 Nov 2012 RANBAXY - Market Perform, in the Q3 CY12 results - Base business margin improvements still awaited
- 08 Nov 2012 GALAPAGOS - Polished to Overt Pfizer's Xelanz, doxycycline and Other Oral JAKs on Efficacy and Safety

RESEARCH LIBRARY



Register to gain access to the full features of this site, including personalized e-mail notifications of our updated research documents.



Register Now >

- レポートを選択していただくと、右のようなレポートの概要が表示されます。

Report Title :	Roche - GSK - EMILIA: TDM1 ready to take over Tykerb
Published Date :	Mar 30, 2012
Document Type	Essentials (ME12033002)
Geographic Zones:	Europe
Countries :	EUROPE
Abstract :	<p>Today, Roche and ImmunoGen announced the topline data from EMILIA study which met the primary end point of Progression free survival significantly. The study explored the use of Trastuzumab Emtansine (TDM1) against Tykerb and Xeloda in more than 900 patients with HER2 positive metastatic breast cancer whose disease progressed after initial treatment with Herceptin and a taxane based chemotherapy (second line setting). We forecast peak sales of \$500m for T-D1 in this indication and this should come at the expense of GSK's Tykerb, which is the current standard of care in this setting. This is the second study in Herceptin failure patients to demonstrate benefit. Earlier, T-D1 in two Phase III studies, VOGEL and KROP had demonstrated an impressive median PFS of 7.3 months and 4.9 months as a third line treatment option in patients who have failed Tykerb and/or Herceptin and/or chemotherapies.</p>
For Subscribers :	Download the full document - PDF File (3, 60 KB)
Price \$:	90
Buy Now :	Purchase Report
Authors:	Vishal Manchanda Dr. Vijayakannan R. Ripple Mehta
Tags & Keywords	Roche, GSK, Tykerb, Xeloda, TDM1, HER-2 positive, Breast cancer, second line

- 同ページ下部の**Purchase Report**をクリックしていただくと、レポート購入 (Buy Reports) ページへと移動します。

Read Abstract	Ticker	Publish Date	Subject	Country	Companies	Pages	Price (\$)	<input type="checkbox"/>
2340	ARBP	20/11/2012	AUROBINDO – Underperform, Great Result, But Still Not Out of Woods	India	Aurobindo	6	140	<input type="checkbox"/>

Free Drugs & Vaccines - Gilead and Abbott vying for the Top Two Slots - Third Place Goes to?

ChronTech Pharma, Inovio, Transgene

1 2 3 4 5 6 7 8 9 10 ...

Check Out Hide

Your Cart Details

Read Abstract	Ticker	Publish Date	Subject	Country	Companies	Pages	Price (\$)	<input type="checkbox"/>
2189	ROG, GSK	30/03/2012	Roche - GSK - EMILIA: TDM1 ready to take over Tykerb	EUROPE	ROCHE, GLAXOSMITHKLINE	3	90	<input checked="" type="checkbox"/>

Online Payment Offline

Name :

Contact No. :

Email :

Reseller Code :

CHECK OUT

- レポート購入ページ下部の**Your Cart Details**にお客様が先ほど選択したレポートが表示されます。
- 確認して頂いた上で間違いがないようでしたら、右画像のようにPrice欄右横のチェックボックスをチェックします。

About Us

Who we are?

Meet the Team

Our Coverage

Gallery

Our Services

BioPharma Outlook™


Institutional Advisory Services


PARA IV Plus™


Japan Database

Strategic Advisory Services

Quick Contacts

 +91 265 232 7096 [India]

 +1 480 263 9400 [USA]

 mp@mpadvisor.com



Add To Cart Hide

Geographic Zones: Keywords:

Ticker: Company:

SEARCH

ADD TO CART

Read Abstract	Ticker	Publish Date	Subject	Country	Companies	Pages	Price (\$)	<input type="checkbox"/>
2345	CIPLA	27/11/2012	CIPLA– Market Perform, Cipla's bid for Cipla Medpro – Valuation Reasonable, No Strategic Benefit	India	CIPLA	2	90	<input type="checkbox"/>
2344	BMJ , PFE	21/11/2012	Bristol-Myers Squibb - Eliquis Approved for SPAF in Europe –Waiting for decision with FDA	United States	Bristol-Myers Squibb, Pfizer	2	90	<input type="checkbox"/>
2343	Natco	21/11/2012	NATCO PHARMA– Outperform, Great Result - More to Come	India	Natco	8	140	<input type="checkbox"/>
2341		20/11/2012	Hepatitis C: UPDATE Post AASLD '12 - Progress in IFN-Free Drugs & Vaccines - Gilead and Abbott vying for the Top Two Slots - Third Place Goes to	All	Abbott,Gilead,Bristol-Myers Squibb, Gilead,Vertex,Boehringer Ingelheim,, Globelimmune, ChronTech Pharma, Inovio, Transgene	7	140	<input type="checkbox"/>

- チェックボックスに緑色のチェックがされた状態で、同ページ上部の**ADD TO CART**をクリックします。
- 確認のメッセージが出ますので、間違いがないようでしたら「OK」を選択してください。
- (注意) 購入希望のレポートにチェックをつけた後は必ず**ADD TO CART**をクリックして次に進んでください。

Read Abstract	Ticker	Publish Date	Subject	Country	Companies	Pages	Price (\$)	
2340	ARBP	20/11/2012	AUROBINDO – Underperform, Great Result, But Still Not Out of Woods	India	Aurobindo	6	140	<input type="checkbox"/>

Vaccines - Gilead and Abbott vying for the Top Two Slots - Third Place Goes to?

Inovio, Transgene

1 2 3 4 5 6 7 8 9 10 ...

Check Out Hide

Your Cart Details

Read Abstract	Ticker	Publish Date	Subject	Country	Companies	Pages	Price (\$)	
2189	ROG, GSK	30/03/2012	Roche - GSK - EMILIA: TDM1 ready to take over Tykerb	EUROPE	ROCHE, GLAXOSMITHKLINE	3	90	<input checked="" type="checkbox"/>

Online Payment Offline

Name :

Contact No. :

Email :

Reseller Code :

About Us

Who we are?
Meet the Team
Our Coverage
Gallery

Our Services

BioPharma Outlook™
Institutional Advisory Services
PARA IV Plus™
Japan Database
Strategic Advisory Services

Quick Contacts

+91 265 232 7096 [India]
+1 480 263 9400 [USA]
mp@mpadvisor.com

- 次に、Your Cart Details下部にある入力ボックスに**Name**、**Email**を入力し、**CHECK OUT**をクリックします。数秒お待ちいただくと、Paypalの支払ページへとリダイレクトされます。
- このときContact No.、Reseller Codeは入力していただく必要はございません。
- (注意)入力ボックス上部のタブが**Online Payment**になっていることを確認した上で、CHECK OUTしてください。

MP Advisors

[English](#)

Your order summary

Descriptions	Amount
Essentials (MEI)2033002 - Roche - 0...	\$90.00
Item price: \$90.00	
Quantity: 1	
<hr/>	
Item total	\$90.00
<hr/>	
Total	\$90.00 USD

Choose a way to pay

PayPal securely processes payments for MP Advisors.

Have a PayPal account?

Log in to your account to pay



Email

PayPal password

[Forgot email or password?](#)

Don't have a PayPal account?

Pay with your debit or credit card as a PayPal guest

[Cancel and return to MP Advisors](#)[Site feedback](#)PayPal - The safer, easier way to pay. For more information, read our [User Agreement](#) and [Privacy Policy](#).

- PayPalアカウントをお持ちでしたら**Email**、**PayPal password**を入力の上、**Log in**してください。
- PayPalアカウントをお持ちでない場合、**Don't have a PayPal account?**をクリックし、クレジットカード情報を入力してください。

Expiration date /

CSC

What is this?

First name

Last name

Address line 1

Address line 2 (optional)

City/State


ZIP code

Phone type

Why is this needed?

Phone number 555-555-1234

Email

Payments processed by 

- クレジットカードでお支払いの場合は、必要事項を全てご記入いただき、下部**Review and Continue**をクリックしてください。
- クレジットカード情報が処理された後、弊社のダウンロードページへとリダイレクトされ、自動でダウンロードが始まります。

- 以下のような事がありましたら、こちらで対処いたしますので早急にお知らせください。
 - 処理の途中でエラーがおきた。
 - 支払いが完了したにもかかわらずダウンロードが開始されない。
 - カートに正しく商品が追加されない
 - その他システム上のトラブル。

- また業務内容、レポート、購入方法に関して疑問、質問等ございましたらお気軽にお問い合わせください。

お問い合わせ先

MP Advisors (旧Mehta Partners)

B/203, Alkapuri Arcade, R. C., Alkapuri, Vadodara-390 007, INDIA

Phone: +1.646.657.1016 [USA]

+91.265.232.0059/232.7096 [India]

E-mail: mp@mpadvisor.com

Web: www.mpadvisor.com